| Aβ | Amyloid Beta |
| ADME | Absorption, distribution, metabolism, and excretion |
| AKI | Acute kidney injury |
| Arg-1 | Arginase-1 |
| ARE | Antioxidant response element |
| BAX | Bcl-2-associated X protein |
| BBB | Blood–brain barrier |
| Bcl-2 | B-cell lymphoma 2 |
| BRP | Brazilian red propolis |
| BV2 | Microglial BV2 cell line |
| CAT | Catalase |
| CD | Cluster of differentiation |
| COX-2 | Cyclooxygenase-2 |
| CXCL1 | C-X-C motif chemokine ligand 1 |
| CXCR3 | C-X-C chemokine receptor type 3 |
| cAMP | Cyclic adenosine monophosphate |
| CYP51 | Sterol 14-alpha-demethylase |
| DMH | 1,2-dimethylhydrazine |
| DOX | Doxorubicin |
| EGF | Epidermal growth gactor |
| EMT | Epithelial–mesenchymal transition |
| ER | Estrogen receptor |
| ERK | Extracellular signal-regulated kinase |
| FOXO3a | Forkhead box O3a |
| FOXP3 | Forkhead box P3 |
| G6PD | Glucose-6-phosphate dehydrogenase |
| GPX4 | Glutathione peroxidase 4 |
| GR | Glutathione reductase |
| GSH | Glutathione |
| HO-1 | Heme oxygenase 1 |
| HSFs | Human skin fibroblasts |
| IC50 | Half maximal inhibitory concentration |
| ICAM-1 | Intercellular adhesion molecule-1 |
| IFN | Interferon |
| IFN-α | Interferon-alpha |
| IFN-β | Interferon-beta |
| IFN-γ | Interferon-gamma |
| IKK | IκB kinase |
| IL-1β | Interleukin 1 beta |
| IL-6 | Interleukin 6 |
| IRF1 | Interferon regulatory factor 1 |
| JAK2 | Janus kinase 2 |
| JNK | c-Jun N-terminal kinase |
| Keap-1 | Kelch-like ECH-associated protein 1 |
| LC3II/I | Microtubule-associated proteins 1A/1B light chain 3B (form II/I) |
| LPS | Lipopolysaccharide |
| M1/M2 | Macrophage phenotypes: M1 (pro-inflammatory), M2 (anti-inflammatory) |
| MCAO | Middle cerebral artery occlusion |
| MCP-1 | Monocyte chemoattractant protein-1 |
| MAPK | Mitogen-activated protein kinase |
| MDA | Malondialdehyde |
| MDCK | Madin–Darby canine kidney |
| MMP-2 | Matrix metallopeptidase 2 |
| MRSA | Methicillin-resistant Staphylococcus Aureus |
| mTOR | Mammalian target of rapamycin |
| NLRP3 | NLR family pyrin domain containing 3 |
| NF-κB | Nuclear factor κB (nuclear factor kappa-light-chain-enhancer of activated B cells) |
| NO | Nitric oxide |
| NQO1 | NAD(P)H quinone dehydrogenase 1 |
| Nrf2 | Nuclear factor erythroid 2–related factor 2 |
| NSCLC | Non-small-cell lung cancer |
| OGD | Oxygen-glucose deprivation |
| P62 | Sequestosome 1 |
| PASI | Psoriasis area and severity index |
| PCNA | Proliferating cell nuclear antigen |
| PD-L1 | Programmed death-ligand 1 |
| PGE2 | Prostaglandin E2 |
| PGES | Prostaglandin E synthase |
| PI3K | Phosphoinositide 3-kinase |
| PTGS2 | Prostaglandin-endoperoxide synthase 2 |
| P-gp | P-glycoprotein |
| ROS | Reactive oxygen species |
| RORγt | RAR-related orphan receptor gamma |
| SIRT3 | Sirtuin 3 |
| Smad2/3 | SMAD family member 2 and 3 |
| SOD | Superoxide dismutase |
| STAT | Signal transducer and activator of transcription |
| TAC | Transverse aortic constriction |
| TGF-β1 | Transforming growth factor beta 1 |
| TLR4 | Toll-like receptor 4 |
| TNF-α | Tumor necrosis factor alpha |
| TR | Trypanothione reductase |
| TSLP | Thymic stromal lymphopoietin |
| VEGF | Vascular endothelial growth factor |
| ZO-1 | Zonula occludens-1 |